Docstoc

Receptos Announces Exclusive Collaboration with Lilly

Document Sample
Receptos Announces Exclusive Collaboration with Lilly Powered By Docstoc
					Receptos Announces Exclusive Collaboration with
Lilly
Collaborative efforts to focus on structure determination and lead generation for high-value G-protein
Coupled Receptor (GPCR) target

January 06, 2011 08:06 AM Eastern Time  

SAN DIEGO--(EON: Enhanced Online News)--Receptos, Inc., a drug discovery and development company,
announced today the establishment of a collaboration with Eli Lilly and Company (NYSE:LLY) to research and
develop small molecule modulators of an undisclosed GPCR target. The companies will jointly identify potential
orally administered candidates for the collaborative target and advance them into pre-clinical development based on
shared structure-based drug design efforts that employ Receptos’s proprietary technology for determining GPCR
crystal structure, exclusively licensed to Receptos from The Scripps Research Institute. Financial details of the
collaboration were not disclosed.

GPCRs have become one of the largest classes of drug targets, and the majority of currently marketed therapeutics
are directed to this family of receptors. Despite these successes, traditional drug discovery methods have failed to
identify small molecule product candidates for many GPCR targets.

"This collaboration with Lilly, an industry leader who has successfully developed expertise in structure-based drug
design, demonstrates Receptos’s leadership position in the area of structure-determination specifically for GPCR
targets,” said Faheem Hasnain, President and Chief Executive Officer of Receptos. “The lead-generation focus of
the collaboration aligns with our company’s strategic plan to contribute to the development of therapeutically relevant
candidates for high-value targets, while maintaining freedom to conduct our own drug development, either with
partners or on an independent basis.” 

About Receptos

Receptos is a biopharmaceutical company developing best- and first-in-class G protein-coupled receptor (GPCR)
therapeutic candidates through information-driven drug discovery, including GPCR structure determination. The
company’s lead program is a best-in-class sphingosine-1-phosphate receptor (S1P1) small molecule, agonist
candidate for autoimmune indications, including multiple sclerosis, anticipated to enter a Phase 1 clinical trial in early
2011. The S1P1 program is supported by the company's recently determined and proprietary high resolution protein
crystal structure of the S1P1 receptor. In November 2009, Receptos completed a $25 million Series A financing
and is supported by a seasoned VC syndicate including ARCH Venture Partners, Flagship Ventures, Lilly Ventures
and Venrock. For more information please visit us at http://www.receptos.com.

Contacts
Receptos, Inc.
James Schmidt, 858-652-5712
info@receptos.com
or
Kureczka/Martin Associates
Joan Kureczka, 415-821-2413
Mobile: 415-690-0210
Joan@kureczka-martin.com
Permalink: http://eon.businesswire.com/news/eon/20110106005770/en/Receptos/Eli-Lilly/GPCR

				
DOCUMENT INFO
Shared By:
Tags:
Stats:
views:74
posted:1/6/2011
language:English
pages:2
Description: SAN DIEGO--(EON: Enhanced Online News)--Receptos, Inc.announced a collaboration with Eli Lilly and Company (NYSE:LLY) to research and develop small molecule modulators of an undisclosed GPCR target. img border='0' title='Add to Google' alt='Add to Google' src='http://images.pheedo
EON: Enhanced Online News EON: Enhanced Online News http://eon.businesswire.com
About At EON: Enhanced Online News, we show you how to make your online press release thrive. If you want to drive traffic to your website, generate sales leads, make an announcement, or promote a new product, EON: Enhanced Online News delivers the online visibility that you need. EON: Enhanced Online News powered by Business Wire.